Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13

Name of entity

OKAPI RESOURCES LIMITED

ABN

21 619 387 085

We (the entity) give ASX the following information.

Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

1. Class of securities issued or to be issued

Performance rights

2. Number of securities issued or to be issued (if known) or maximum number which may be issued

900,000 performance rights

3. Principal terms of the securities (e.g. if options, exercise price and expiry date; if partly paid securities, the amount outstanding and due dates for payment; if convertible securities, the conversion price and dates for conversion)

Performance Rights issued in accordance with the Okapi Resources Limited Incentive Performance Rights Plan, approved by shareholders at the 2017 AGM. On vesting, one Performance Right is converted to one fully paid ordinary share in the Company for nil cash consideration.

The general vesting condition is that the employee or consultant must be employed or engaged respectively for a period of 12 months from the date of this offer, as well as the following additional “specific” vesting condition for each tranche:

**Tranche One** – not applicable;

**Tranche Two** – the Company achieving and maintaining a market capitalisation of $18 million or more for a continuous period of 30 days on or before 31 December 2021; and

**Tranche Three** – the Company achieving and maintaining a market capitalisation of $24m or more for a continuous period of 30 days on or before 31 December 2021.

The performance rights expire 5 years after date of grant unless the specific performance conditions states otherwise.

+ See chapter 19 for defined terms.
### Appendix 3B

**New issue announcement**

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
</table>
| 4 | Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?  
If the additional *securities do not rank equally, please state:  
* the date from which they do  
* the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment  
* the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment | N/A |
| 5 | Issue price or consideration | No cash consideration |
| 6 | Purpose of the issue  
(If issued as consideration for the acquisition of assets, clearly identify those assets) | Performance Rights provided to key management and consultants as incentives on achieving specified vesting measures/conditions within a specified period. |
| 6a | Is the entity an *eligible entity that has obtained security holder approval under rule 7.1A?  
If Yes, complete sections 6b – 6h in relation to the *securities the subject of this Appendix 3B, and comply with section 6i | No |
| 6b | The date the security holder resolution under rule 7.1A was passed | N/A |
| 6c | Number of *securities issued without security holder approval under rule 7.1 | N/A |
| 6d | Number of *securities issued with security holder approval under rule 7.1A | N/A |
| 6e | Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting) | N/A |
| 6f | Number of *securities issued under an exception in rule 7.2 | 900,000 Performance Rights issued to senior mgmt. and consultants of OKR under its performance rights plan. |

*See chapter 19 for defined terms.
6g If securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the issue date and both values. Include the source of the VWAP calculation.

6h If securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements

6i Calculate the entity’s remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements

7 Issue dates

Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.

Cross reference: item 33 of Appendix 3B.

<table>
<thead>
<tr>
<th>Number</th>
<th>Class</th>
</tr>
</thead>
<tbody>
<tr>
<td>25,500,010</td>
<td>Ordinary fully paid shares</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Number</th>
<th>Class</th>
</tr>
</thead>
<tbody>
<tr>
<td>4,200,000</td>
<td>Ordinary fully paid shares Escrowed to 27 Sept 2019</td>
</tr>
<tr>
<td>2,000,000</td>
<td>Ordinary fully paid shares Escrowed to 27 Sept 2018</td>
</tr>
<tr>
<td>500,000</td>
<td>Ordinary fully paid shares Escrowed to 14 June 2018</td>
</tr>
<tr>
<td>5,100,000</td>
<td>Performance rights Escrowed to 27 Sept 2019</td>
</tr>
<tr>
<td>900,000</td>
<td>Performance rights Escrowed to 27 Sept 2019</td>
</tr>
</tbody>
</table>

8 Number and class of all securities quoted on ASX (including the securities in section 2 if applicable)

<table>
<thead>
<tr>
<th>Number</th>
<th>Class</th>
</tr>
</thead>
<tbody>
<tr>
<td>25,500,010</td>
<td>Ordinary fully paid shares</td>
</tr>
</tbody>
</table>

9 Number and class of all securities not quoted on ASX (including the securities in section 2 if applicable) *

10 Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests) N/A.

+ See chapter 19 for defined terms.
### Part 2 - Pro rata issue

<p>| | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>11</td>
<td>Is security holder approval required?</td>
<td>N/A</td>
</tr>
<tr>
<td>12</td>
<td>Is the issue renounceable or non-renounceable?</td>
<td>N/A</td>
</tr>
<tr>
<td>13</td>
<td>Ratio in which the securities will be offered</td>
<td>N/A</td>
</tr>
<tr>
<td>14</td>
<td>Class of securities to which the offer relates</td>
<td>N/A</td>
</tr>
<tr>
<td>15</td>
<td>Record date to determine entitlements</td>
<td>N/A</td>
</tr>
<tr>
<td>16</td>
<td>Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?</td>
<td>N/A</td>
</tr>
<tr>
<td>17</td>
<td>Policy for deciding entitlements in relation to fractions</td>
<td>N/A</td>
</tr>
<tr>
<td>18</td>
<td>Names of countries in which the entity has security holders who will not be sent new offer documents</td>
<td>N/A</td>
</tr>
<tr>
<td></td>
<td>Note: Security holders must be told how their entitlements are to be dealt with. Cross reference: rule 7.7.</td>
<td></td>
</tr>
<tr>
<td>19</td>
<td>Closing date for receipt of acceptances or renunciations</td>
<td>N/A</td>
</tr>
<tr>
<td>20</td>
<td>Names of any underwriters</td>
<td>N/A</td>
</tr>
<tr>
<td>21</td>
<td>Amount of any underwriting fee or commission</td>
<td>N/A</td>
</tr>
<tr>
<td>22</td>
<td>Names of any brokers to the issue</td>
<td>N/A</td>
</tr>
<tr>
<td>23</td>
<td>Fee or commission payable to the broker to the issue</td>
<td>N/A</td>
</tr>
<tr>
<td>24</td>
<td>Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders</td>
<td>N/A</td>
</tr>
<tr>
<td>25</td>
<td>If the issue is contingent on security holders’ approval, the date of the meeting</td>
<td>N/A</td>
</tr>
</tbody>
</table>

+ See chapter 19 for defined terms.
<table>
<thead>
<tr>
<th></th>
<th>Description</th>
<th>Date/Information</th>
</tr>
</thead>
<tbody>
<tr>
<td>26</td>
<td>Date entitlement and acceptance form and offer documents will be sent to persons entitled</td>
<td>N/A</td>
</tr>
<tr>
<td>27</td>
<td>If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders</td>
<td>N/A</td>
</tr>
<tr>
<td>28</td>
<td>Date rights trading will begin (if applicable)</td>
<td>N/A</td>
</tr>
<tr>
<td>29</td>
<td>Date rights trading will end (if applicable)</td>
<td>N/A</td>
</tr>
<tr>
<td>30</td>
<td>How do security holders sell their entitlements <em>in full</em> through a broker?</td>
<td>N/A</td>
</tr>
<tr>
<td>31</td>
<td>How do security holders sell <em>part</em> of their entitlements through a broker and accept for the balance?</td>
<td>N/A</td>
</tr>
<tr>
<td>32</td>
<td>How do security holders dispose of their entitlements (except by sale through a broker)?</td>
<td>N/A</td>
</tr>
<tr>
<td>33</td>
<td>+Issue date</td>
<td>N/A</td>
</tr>
</tbody>
</table>

+ See chapter 19 for defined terms.
Part 3 - Quotation of securities
You need only complete this section if you are applying for quotation of securities

34 Type of securities
   (tick one)

(a) checkbox  'Securities described in Part 1

(b) checkbox  All other securities
   Example: restricted securities at the end of the escrow period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities

Entities that have ticked box 34(a)

Additional securities forming a new class of securities
   Tick to indicate you are providing the information or documents

35 checkbox  If the securities are equity securities, the names of the 20 largest holders of the additional securities, and the number and percentage of additional securities held by those holders

36 checkbox  If the securities are equity securities, a distribution schedule of the additional securities setting out the number of holders in the categories
   1 - 1,000
   1,001 - 5,000
   5,001 - 10,000
   10,001 - 100,000
   100,001 and over

37 checkbox  A copy of any trust deed for the additional securities

+ See chapter 19 for defined terms.
Quotation agreement

1. Quotation of our additional securities is in ASX’s absolute discretion. ASX may quote the securities on any conditions it decides.

2. We warrant the following to ASX.
   - The issue of the securities to be quoted complies with the law and is not for an illegal purpose.
   - There is no reason why those securities should not be granted quotation.
   - An offer of the securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.
     
     Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty
     
     - Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any securities to be quoted and that no-one has any right to return any securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the securities be quoted.
     
     - If we are a trust, we warrant that no person has the right to return the securities to be quoted under section 1019B of the Corporations Act at the time that we request that the securities be quoted.

3. We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.

4. We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before quotation of the securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here:  
Date: 12 January 2017

Print name:  
Craig Nelmes  
Company Secretary
Appendix 3B – Annexure 1

Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12  Amended 04/03/13

Part 1

<table>
<thead>
<tr>
<th>Rule 7.1 – Issues exceeding 15% of capital</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Step 1: Calculate “A”, the base figure from which the placement capacity is calculated</strong></td>
</tr>
<tr>
<td>Insert number of fully paid ordinary securities on issue 12 months before the issue date or date of agreement to issue</td>
</tr>
<tr>
<td>Add the following:</td>
</tr>
<tr>
<td>• Number of fully paid ordinary securities issued in that 12 month period under an exception in rule 7.2</td>
</tr>
<tr>
<td>• Number of fully paid ordinary securities issued in that 12 month period with shareholder approval</td>
</tr>
<tr>
<td>• Number of partly paid ordinary securities that became fully paid in that 12 month period</td>
</tr>
<tr>
<td>Note:</td>
</tr>
<tr>
<td>• Include only ordinary securities here – other classes of equity securities cannot be added</td>
</tr>
<tr>
<td>• Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</td>
</tr>
<tr>
<td>• It may be useful to set out issues of securities on different dates as separate line items</td>
</tr>
<tr>
<td>Subtract the number of fully paid ordinary securities cancelled during that 12 month period</td>
</tr>
<tr>
<td>“A”</td>
</tr>
</tbody>
</table>

+ See chapter 19 for defined terms.
<table>
<thead>
<tr>
<th>Step 2: Calculate 15% of “A”</th>
</tr>
</thead>
<tbody>
<tr>
<td>“B”</td>
</tr>
<tr>
<td>Multiply “A” by 0.15</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Step 3: Calculate “C”, the amount of placement capacity under rule 7.1 that has already been used</th>
</tr>
</thead>
<tbody>
<tr>
<td>Insert number of equity securities issued or agreed to be issued in that 12 month period <em>not counting</em> those issued:</td>
</tr>
<tr>
<td>• Under an exception in rule 7.2</td>
</tr>
<tr>
<td>• Under rule 7.1A</td>
</tr>
<tr>
<td>• With security holder approval under rule 7.1 or rule 7.4</td>
</tr>
<tr>
<td>Note:</td>
</tr>
<tr>
<td>• This applies to equity securities, unless specifically excluded – not just ordinary securities</td>
</tr>
<tr>
<td>• Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</td>
</tr>
<tr>
<td>• It may be useful to set out issues of securities on different dates as separate line items</td>
</tr>
<tr>
<td>“C”</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Step 4: Subtract “C” from [“A” x “B”] to calculate remaining placement capacity under rule 7.1</th>
</tr>
</thead>
<tbody>
<tr>
<td>“A” x 0.15</td>
</tr>
<tr>
<td>Subtract “C”</td>
</tr>
<tr>
<td>Total [“A” x 0.15] – “C”</td>
</tr>
</tbody>
</table>

+ See chapter 19 for defined terms.
Part 2

<table>
<thead>
<tr>
<th>Rule 7.1A – Additional placement capacity for eligible entities</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Step 1: Calculate “A”, the base figure from which the placement capacity is calculated</strong></td>
</tr>
<tr>
<td>“A”</td>
</tr>
<tr>
<td>Note: number must be same as shown in Step 1 of Part 1</td>
</tr>
</tbody>
</table>

| **Step 2: Calculate 10% of “A”** |
| “D” | 0.10 |
| Note: this value cannot be changed |
| Multiply “A” by 0.10 | N/A |

| **Step 3: Calculate “E”, the amount of placement capacity under rule 7.1A that has already been used** |
| Insert number of “equity securities issued or agreed to be issued in that 12 month period under rule 7.1A |
| Notes: |
| • This applies to equity securities – not just ordinary securities |
| • Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed |
| • Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained |
| • It may be useful to set out issues of securities on different dates as separate line items |
| “E” | N/A |

| **Step 4: Subtract “E” from [“A” x “D”] to calculate remaining placement capacity under rule 7.1A** |
| “A” x 0.10 | N/A |
| Note: number must be same as shown in Step 2 |
| Subtract “E” | N/A |
| Note: number must be same as shown in Step 3 |
| Total [“A” x 0.10] – “E” | N/A |
| Note: this is the remaining placement capacity under rule 7.1A |

+ See chapter 19 for defined terms.